First Cardiology Department, Hippokration General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
University Cardiology, AOU Citta della Salute e della Scienza di Torino, Torino 10126, Italy.
Curr Pharm Des. 2018;24(6):702-709. doi: 10.2174/1381612824666180116101823.
Colchicine is an old drug originally employed for the treatment of inflammatory disorders such as acute gout and familiar Mediterranean fever.
In the past few decades, colchicine has been at the forefront of the pharmacotherapy of several cardiac diseases, including acute and recurrent pericarditis, coronary artery disease, prevention of atrial fibrillation and heart failure. In this review, we have summarized the current evidence based medicine and guidelines recommendations in the specific context of pericardial syndromes.
Colchicine has been firstly engaged in the treatment of recurrent pericarditis of viral, idiopathic and autoimmune origin. Shortly thereafter colchicine use has been expanded to the primary prevention of recurrences in patients with a first episode of pericarditis depicting similarly good results. The acquisition of high quality scientific data in the course of time from prospective randomized placebo-controlled trials and metanalyses have established colchicine as first line treatment option in acute and recurrent pericarditis, on top of the conventional treatment. The only concerns related to the use of colchicine are the side effects (mainly gastrointestinal intolerance) which although generally not serious, may account for treatment withdrawal in some cases.
Colchicine has been established as a first line medication in the treatment of acute (first episode) and recurrent pericarditis on top of the conventional treatment as well as for the prevention of postpericardiotomy syndrome. It depicts a good safety profile with gastrointestinal intolerance being the most common side effect.
秋水仙碱是一种古老的药物，最初用于治疗炎症性疾病，如急性痛风和熟悉的地中海热。
在过去的几十年中，秋水仙碱一直是几种心脏病药物治疗的前沿药物，包括急性和复发性心包炎、冠状动脉疾病、预防心房颤动和心力衰竭。在这篇综述中，我们总结了基于循证医学和指南建议的特定心包综合征背景下的当前证据。
秋水仙碱最初用于治疗病毒性、特发性和自身免疫性复发性心包炎。此后不久，秋水仙碱的使用范围扩大到了首次发生心包炎的患者的一级预防复发，同样取得了良好的效果。前瞻性随机安慰剂对照试验和荟萃分析的高质量科学数据的积累，确立了秋水仙碱作为急性和复发性心包炎的一线治疗选择，在常规治疗之上。使用秋水仙碱唯一的顾虑是副作用（主要是胃肠道不耐受），尽管通常不严重，但在某些情况下可能导致治疗中断。
秋水仙碱已被确立为急性（首次发作）和复发性心包炎的一线药物，在常规治疗之上，也可用于预防心包切开术后综合征。它具有良好的安全性，胃肠道不耐受是最常见的副作用。
